摘要
目的探讨高龄老年患者应用东菱克栓酶的疗效和安全性。方法所有患者分成对照组(30例)和降纤组(24例),降纤组首次用东菱克栓酶(DF-521)10BU,5BU,5BU,隔日静滴,疗程5d。其他常规用药两组相同,疗程14d。用药前及第14天观察血常规、血生化、血糖、凝血常规、头颅MRI+DWI等。结果降纤组神经功能改善明显优于对照组(P〈0.05);降纤组用药前后在血常规、肝肾功能、血糖、血脂、凝血酶原时间等方面差异无统计学意义(P〉0.05)。结论对于高龄老年脑梗死患者,东菱克栓酶依然是安全而有效的治疗药物。
Objective To investgate the efficacy and safety of Tobishi Batroxobin in treating cerebral Infarction of advanced age. Methods All patients were divided into,control group (30 patients) and defibrase group(24 patients).Patients in defibrase group were treated with Tobishi Batroxobin,an initial intravenousinfusion of defibrase 10BU and subsequent infusion 5BU on the 3rd,5th day respectively,the total course were 5 d.The conventional therapy in the two groups were the same.Two groups were both ob- served with blood routine examination,blood biochemistry,blood glucose,blood clotting,MRI+DWI before treatment and 14 days af- ter treatment.Results The neurological functional assessment of patients in defibrase group were obviously improved than control group,the difference was significant(P 〈 0.05).The difference in blood routine examination,blood biochemistry,blood glucose,blood clotting was not significant in defibrase group before and after treatment.Conclutions Tobishi Batroxobin is effective and safe to advanced age with cerebral infarction.
出处
《中国药业》
CAS
2013年第A01期61-62,共2页
China Pharmaceuticals
关键词
高龄老年
脑梗死
东菱克栓酶
advanced age
cerebral infarction
Tobishi Batroxobin